●GENESIS v2.02
194+ countries covered8+ model replicasDALYs or QALYsLocal currency or international dollarsKnow what a health intervention
is worth in minutes
See if drugs, vaccines, tests, or programs are cost-saving or cost-effective, using replicas of peer-reviewed health economic models, localized to your country and customizable with your data.
Free for LMIC public sector · Everyone else gets 3 free analyses
I. Curated Library
A library that grows with your priorities.
Don't see your disease area? Sponsor or request a model
HIV/AIDS
CEPAC (Kimmel et al., 2010)
HPV Vaccines
Elbasha et al., 2007
RSV in Young Children
Koltai et al., 2023
Type 2 Diabetes
UK Prospective Diabetes Study (UKPDS)
Chronic Kidney Disease
Tisdale et al., 2022
Obesity
DOC-M (Kim et al., 2023)
MASLD / MASH
Chhatwal & Le et al.
Alzheimer's Disease
IPECAD Consortium Model
Editor's note
GENESIS doesn't replace the priority-setting institution. It replaces the spreadsheet inside it.
II. Workflow
From question to insight in minutes.
In as little as 4 steps. The model is already built.
Choose your model
Pick a faithful replication of a peer-reviewed disease model.
Select your country
One click loads demographics, life tables, costs, and willingness-to-pay thresholds for your country.
Customize with your data
Optionally inject local cost, morbidity or survey data to better represent your target location.
Run the analyses
Get rapid insights through intuitive visualizations and tables, a one pager or a detailed technical report.
III. Outputs
What you get
Every analysis produces intuitive visualizations, a one-page brief, and a publication-grade technical report. Click thumbnails to see examples
i. Intuitive Visualizations & Tables
Find a price that is cost-saving or cost-effective
ii. Executive Memo
One pager for leadership & busy executives
iii. Technical Report
iDSI Reference Case, Gates Reference Case & CHEERS 2022 standards
Privacy
Your analysis is yours alone. We don’t sell it or retain it on our servers.
IV. Why GENESIS
The barriers are gone. The rigor stays.
Time, cost and expertise no longer stand between you and an answer.
Minutes, not months
Each answer takes minutes at no extra cost, not the months and budget a custom-built model needs.
Run it yourself
Your own staff run it in a browser, any time, with no modeling team and no patient data.
The bigger picture
See what drives each result, compare options side by side, and run one model across a region.
Nothing hidden
Inputs are cited and used as published, results are tested and shown with their limits, and no generative AI is used.
V. Validation
Different methods, the same call.
Every replica reaches the same coverage decision as its published benchmark, whether yes or no.
HIV/AIDS
2
3 of 3
South Africa
Community adherence groups and CrAg screening reach the same calls as You et al. and Jarvis et al.
You et al.Open Forum Infect Dis · 2026
Community adherence groups
$274–604/DALY
$620/DALY
$6.6K/DALY
Aligned
Cost-Effectiveness of Differentiated Service Delivery for HIV Treatment: A Combined Mathematical Modeling Study of Four African Settings
SourceModeled community adherence groups vs clinic-based care in South Africa. OFID Original Article →
GENESISReplicated the You comparison of adherence groups vs clinic care in South Africa.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
Jarvis et al.PLOS ONE · 2013
CrAg screening
Cost-saving
Cost-saving
$6.6K/DALY
Aligned
Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa
SourceModeled CrAg screening vs standard care at CD4 below 100 in South Africa. PLOS ONE Original Article →
GENESISReplicated Jarvis's CD4-below-100 cohort, inputs and first-year horizon in South Africa.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
Botswana
CrAg screening reaches the same call as Tenforde et al.
Tenforde et al.Wellcome Open Res · 2019
CrAg screening
$2/DALY
Cost-saving
$7.8K/DALY
Aligned
Cost-effectiveness of reflex laboratory-based cryptococcal antigen screening for the prevention and treatment of cryptococcal meningitis in Botswana
SourceModeled CrAg screening vs none at CD4 below 100 in Botswana. Wellcome Open Res Original Article →
GENESISReplicated Tenforde's CD4-below-100 cohort, inputs and one-year horizon in Botswana.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
HPV Vaccines
1
1 of 1
US
Brisson et al.JNCI · 2015
HPV vaccine (9- vs. 4-valent)
Cost-saving
Cost-saving
$100K/QALY
Aligned
Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States
SourceEvaluated switching from 4-valent to 9-valent HPV vaccination in the US. JNCI Original Article →
GENESISReplicated the Brisson scenario for 4v vs 9v gender-neutral HPV vaccination in the US.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
RSV in Young Children
3
6 of 6
Cameroon
Nirsevimab and RSVpreF reach the same call as Shaaban et al.
Shaaban et al.J Glob Health · 2026
Nirsevimab
$500/DALY
$497/DALY
$782/DALY
Aligned
Shaaban et al.J Glob Health · 2026
RSVpreF
$500/DALY
$487/DALY
$782/DALY
Aligned
Impact and cost-effectiveness of two interventions to prevent paediatric respiratory syncytial virus disease in Cameroon: a modelling approach
SourceModeled nirsevimab and maternal RSVpreF vs no immunization in Cameroon. J Glob Health Original Article →
GENESISReplicated the Shaaban burden, coverage, efficacy and cost inputs for nirsevimab and RSVpreF vs no immunization in Cameroon.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
Nepal
Nirsevimab (no delay) and RSVpreF reach the same call as Rave et al.
Rave et al.J Glob Health · 2025
Nirsevimab (no delay)
$371/DALY
$383/DALY
$450/DALY
Aligned
Rave et al.J Glob Health · 2025
RSVpreF
$387/DALY
$374/DALY
$450/DALY
Aligned
Cost-effectiveness of introducing a maternal vaccine or long-acting monoclonal antibody to prevent infant respiratory syncytial virus disease in Nepal
SourceModeled maternal RSVpreF and nirsevimab vs no immunization in Nepal; the nirsevimab figure is its no-delay scenario. J Glob Health Original Article →
GENESISReplicated the Rave burden, coverage, efficacy and cost inputs for nirsevimab at birth and RSVpreF vs no immunization in Nepal.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
Mozambique
Nirsevimab and RSVpreF reach the same call as Guimarães et al.
Guimarães et al.J Glob Health Econ Policy · 2025
Nirsevimab
$289/DALY
$317/DALY
$249/DALY
Aligned
Guimarães et al.J Glob Health Econ Policy · 2025
RSVpreF
$288/DALY
$285/DALY
$249/DALY
Aligned
Cost-effectiveness of respiratory syncytial virus prevention strategies in Mozambique: a modelling study
SourceModeled maternal RSVpreF and nirsevimab vs no immunization in Mozambique. J Glob Health Econ Policy Original Article →
GENESISReplicated the Guimarães burden, coverage, efficacy and cost inputs for nirsevimab and RSVpreF vs no immunization in Mozambique.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
Type 2 Diabetes
1
1 of 1
China
Wang et al.Diabetes Obes Metab · 2025
Tirzepatide vs Semaglutide
$445K–$544K/QALY
$329K/QALY
$29K/QALY
Aligned
Cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China
SourceCompared tirzepatide vs semaglutide add-on to metformin in Chinese T2D adults. DOM Original Article →
GENESISReplicated the Wang head-to-head for metformin + tirzepatide vs metformin + semaglutide in China.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
Chronic Kidney Disease
1
1 of 1
US
Tisdale et al.J Gen Intern Med · 2022
Dapagliflozin
$60,000/QALY
$59,700/QALY
$100K/QALY
Aligned
Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
SourceCompared dapagliflozin plus standard care vs standard care alone in US adults with non-diabetic CKD. Original article →
GENESISReplicated the Tisdale model for dapagliflozin vs standard of care in the US, run on the source's base-case design (five prevalence-weighted age cohorts, the source's age- and sex-specific baseline costs and utilities).
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
Obesity
1
2 of 2
US
Hwang et al.JAMA Health Forum · 2025
Tirzepatide
$197,023/QALY
$155,000/QALY
$100K/QALY
Aligned
US
Hwang et al.JAMA Health Forum · 2025
Semaglutide
$467,676/QALY
$429,000/QALY
$100K/QALY
Aligned
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
SourceLifetime simulation of four antiobesity medications vs lifestyle modification. JAMA Original Investigation →
GENESISReplicated the DOC-M framework for tirzepatide and semaglutide vs lifestyle modification in the US.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
MASLD / MASH
1
1 of 1
US
Le et al.JAMA Netw. Open · 2025
Resmetirom
$140,134/QALY
$140,328/QALY
$100K/QALY
Aligned
Value-Based Pricing of Resmetirom for Metabolic Dysfunction-Associated Steatotic Liver Disease
SourceModeled resmetirom for MASH F2–F3 adults, US payer perspective. JAMA Network Open Original Article →
GENESISReplicated Le et al. as a patient-level microsimulation; resmetirom vs standard of care in the US.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
Alzheimer's Disease
2
3 of 3
UK
Donanemab reaches the same call as NICE.
NICEDraft Guidance · 2024
Donanemab
~£180,000/QALY
£223,500/QALY
£30K/QALY
Aligned
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease
SourceEvaluated donanemab for early AD using NHS reference costs. NICE Draft Guidance →
GENESISReplicated the IPECAD framework for donanemab vs standard of care in the UK.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
US
Lecanemab and donanemab reach the same call as ICER.
ICERDraft Report · 2022
Lecanemab
$258,000/QALY
$367,900/QALY
$100K/QALY
Aligned
ICERDraft Report · 2022
Donanemab
$139,000/QALY
$385,600/QALY
$100K/QALY
Aligned
Beta-Amyloid Antibodies for Early Alzheimer's Disease — Draft Evidence Report
SourceModeled lecanemab and donanemab vs supportive care for early AD in the US. Original article →
GENESISReplicated the IPECAD framework for lecanemab and donanemab vs standard of care in the US.
VerdictAligned recommendations despite different modeling choices, inputs and timelines.
All models
8
18 of 18
Thesis
From priority decisions made on faith, to priority decisions made on evidence.
VI. Audiences
For those who set priorities & the people they serve.
Different questions, the same defensible standard.
Public sector
Compare products and test prices while the committee is still in the room.
HTA agencies & payers
Benchmark any submission against an independent replica of a peer-reviewed model.
Research & advisory
CHEERS-compliant analyses on your own data, ready for journals and grants.
Pharma & biotech teams
Forecast value with your own efficacy data for go/no-go calls and pricing. Your data stays private.
VII. Access
Open access for those who need it most.
Commercial subscribers and donors fund sponsored Mission access.
Free Trial
$0
No credit card required
- 10K simulated patients
- 1K PSA iterations
- All models in 194+ countries
- Custom drugs, vaccines, and programs
- Ask your AI assistant to run analyses
- PDF reports only
- 3 lifetime analyses
Mission
$0 (Sponsored)
For LMIC public sector & regional bodies
- Up to 100K simulated patients
- 1K PSA iterations
- All models in 194+ countries
- Custom drugs, vaccines, and programs
- Ask your AI assistant to run analyses
- PDF & white-label reports
- Unlimited analyses
Commercial
$1,000
per user / month
- Up to 100K simulated patients
- 1K PSA iterations
- All models in 194+ countries
- Custom drugs, vaccines, and programs
- Ask your AI assistant to run analyses
- PDF & white-label reports
- Unlimited analyses